In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Cytosorbents (CTSO), with a price target of $13.00. The company’s shares closed last Tuesday at $9.41.
According to TipRanks.com, CFA is a 1-star analyst with an average return of -4.0% and a 40.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as ThermoGenesis Holdings, CASI Pharmaceuticals, and Gritstone Oncology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents with a $14.33 average price target, representing a 51.0% upside. In a report issued on July 23, B.Riley FBR also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
Based on Cytosorbents’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.71 million and GAAP net loss of $3.45 million. In comparison, last year the company earned revenue of $5.19 million and had a GAAP net loss of $4.88 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
